FDC approves Rs 120 crore buyback after strong Q2 results

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

FDC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+6.8%Reaction day

₹353.00

prior close

₹385.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%+6.7% vs market

Pharmaceuticals peers, median of 170sector+0.6%+6.2% vs sector

On the reaction day the stock moved 6.7 pts more than Nifty Microcap 250 and 6.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-3.8

10m

-4.3

15m

-4.2

30m

-3.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+6.8+0.1+6.7+0.6+6.2

Next day

+6.8+0.7+6.1+1.1+5.7

+7.1pendingpending-0.3+7.3

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q2 revenue rose 21% to Rs 572.14 crore from Rs 473.03 crore, while profit attributable to owners surged to Rs 43.06 crore from Rs 20.97 crore. Half-year cash generated from operations was Rs 251.26 crore versus negative Rs 1.94 crore. The board approved a proportionate buyback of up to 24 lakh shares, 1.47% of capital, at Rs 500 each, capped at Rs 120 crore. Record date is November 13, 2026. Promoters intend to participate.

Likely market impact

Profit, operating cash flow and a promoter-backed buyback may aid sentiment and per-share value, but up to Rs 120 crore of cash will be used.